In this issue:
Front-line nivolumab/ipilimumab elicits deep, durable responses in metastatic MSI-H/dMMR disease
Reduced survival with delays to surgery in neoadjuvant non-responders with rectal cancer
Treatment break following palliative intent induction therapy doesn’t impact survival
No survival benefit to adjuvant chemotherapy in liver-only metastatic disease
EPOCH demonstrates that TARE slows progression of CRC liver metastases
FOCUS4-C: Maintenance adavosertib slows growth of TP53/RAS-mutated CRC
PANAMA finds PFS benefit to addition of panitumumab to FU/FA maintenance
TAS-116 plus nivolumab has anti-tumour activity in refractory microsatellite stable CRC
Triplet chemotherapy plus bevacizumab underutilised in the Netherlands
COVID lockdowns increase tumour burden at diagnosis
Please login below to download this issue (PDF)